For differentiating between LM and non‐LM in stage IV patients, serum CEACAM6 had sensitivity of 66.7% and specificity of 100.0% by setting a cutoff value of 3.967 ng/ml. This evidence concerns the gene CEACAM6 and lymphangioma.